Program
Ranibizumab
Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.
Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 560 open or running | phase 4since Jul 19, 2007 | Jan 11, 2006 | none ahead |
| Hoffmann-La Rocheits history only | 244 open or running | phase 4since Jan 13, 2011 | Mar 24, 2003 | Feb 4, 2027phase 3 · NCT04657289 |
| AbbVieits history only | 31 open or running | phase 4since Aug 31, 2011 | Oct 16, 2008 | Jul 2031phase 2 · NCT05210803 |
| Samsung Bioepisits history only | 20 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Santen Pharmaceuticalits history only | 20 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| AO GENERIUMits history only | 11 open or running | phase 3since Nov 30, 2020 | Nov 30, 2020 | none ahead |
| Bioeqits history only | 10 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | none ahead |
| Cynosure Lutronicits history only | 10 open or running | phase 4since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Formyconits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| Oraya Therapeuticsits history only | 10 open or running | no phasesince Jan 24, 2012 | Jan 24, 2012 | none ahead |
| Pfenexits history only | 10 open or running | phase 2since Apr 17, 2014 | Apr 17, 2014 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| QLTits history only | 10 open or running | phase 2since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Shanghai Biomabs Pharmaceuticalits history only | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| Xbrane Biopharma ABits history only | 10 open or running | phase 3since Jan 8, 2019 | Jan 8, 2019 | none ahead |
Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Jan 11, 2006.
- Oct 18, 20132 phase 3 studiesNCT01976338, NCT01976312
- Nov 12, 2013Phase 4 study in Macular DegenerationNCT01986907 · 1,049 enrolled · Italy
- Jan 8, 20142 phase 3 studiesNCT02032173, NCT02034006
- Mar 27, 2014Phase 4 study in Macular DegenerationNCT02130024 · 281 enrolled · Australia
- Jun 10, 2014Phase 4 study in Macular DegenerationNCT02161575 · 103 enrolled · Germany, United Kingdom
- Oct 2, 20142 phase 4 studiesNCT02258009, NCT02257632
- Oct 3, 2014Phase 3 study in Vision DisordersNCT02259088 · 384 enrolled · China
- Jan 12, 2015Phase 4 study in Diabetic RetinopathyNCT02366468 · 135 enrolled · Germany
- Feb 18, 2015Phase 3 study in Retinopathy of PrematurityNCT02375971 · 224 enrolled · United States, Austria, Belgium and more
- Jul 30, 2015Phase 4 study in Macular DegenerationNCT02577107 · 12 enrolled · China
- Dec 1, 2015Phase 3 study in Retinopathy of PrematurityNCT02640664 · 180 enrolled · United States, Austria, Belgium and more
- Dec 16, 2015Phase 4 study in Neovascularization, PathologicNCT02634970
- Jul 22, 2016Phase 4 study in Visual Impairment Due to Diabetic Macular EdemaNCT02878681
- Apr 23, 2019Phase 2 study in Macular DegenerationNCT03927690 · 91 enrolled · United States, Germany, Puerto Rico and more
TargetBeta
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
All 56 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03927690Macular Degeneration · United States, Germany, Puerto Rico and more | 2 | Completed | Jun 17, 2022 | 91 |
| NCT02878681Visual Impairment Due to Diabetic Macular Edema | 4 | Withdrawn | Sep 2017 | 0 |
| NCT02634970Neovascularization, Pathologic | 4 | Withdrawn | Dec 2017 | 0 |
| NCT02640664Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Apr 21, 2022 | 180 |
| NCT02577107Macular Degeneration · China | 4 | Completed | Jul 9, 2016 | 12 |
| NCT02375971Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Dec 14, 2017 | 224 |
| NCT02366468Diabetic Retinopathy · Germany | 4 | Completed | Jun 8, 2017 | 135 |
| NCT02259088Vision Disorders · China | 3 | Completed | Jan 17, 2017 | 384 |
| NCT02258009Visual Impairment Due to Diabetic Macular Edema · Germany | 4 | Withdrawn | Oct 2016 | 0 |
| NCT02257632Wet Age-Related Macular Degeneration · Germany | 4 | Completed | Mar 20, 2017 | 41 |
| NCT02161575Macular Degeneration · Germany, United Kingdom | 4 | Completed | Sep 14, 2017 | 103 |
| NCT02130024Macular Degeneration · Australia | 4 | Completed | Nov 15, 2017 | 281 |
| NCT02034006Myopia, Degenerative · Italy | 3 | Completed | Jul 15, 2016 | 200 |
| NCT02032173Macular Edema · France | 3 | Terminated | Apr 29, 2015 | 31 |
| NCT01986907Macular Degeneration · Italy | 4 | Completed | Jun 15, 2016 | 1,049 |
| NCT01972789Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD · Australia | 4 | Completed | Feb 28, 2017 | 349 |
| NCT01976338Macular Edema · China, Hong Kong, Indonesia and more | 3 | Completed | Mar 28, 2016 | 283 |
| NCT01976312Retinal Vein Occlusion · China, Hong Kong, India and more | 3 | Completed | Mar 14, 2016 | 252 |
| NCT01958918Neovascular Age-related Macular Degeneration · Austria, Belgium, Denmark and more | 4 | Completed | Nov 22, 2016 | 712 |
| NCT01948830Macular Degeneration · Belgium, Chile, Croatia and more | 3 | Completed | Nov 19, 2015 | 650 |
| NCT01922102Choroidal Neovascularization · China, Hong Kong, India and more | 3 | Completed | Sep 14, 2016 | 457 |
| NCT01908816Choroidal Neovascularization · France | 3 | Completed | Jan 8, 2016 | 270 |
| NCT01846299Macular Edema · Australia, Belgium, Canada and more | 3 | Completed | Sep 2015 | 181 |
| NCT01840410Choroidal Neovascularization · Australia, Canada, Czech Republic and more | 3 | Completed | Nov 2015 | 183 |
| NCT01780935Neovascular Age-related Macular Degeneration · Argentina, Austria, Canada and more | 3 | Completed | Jul 9, 2015 | 671 |
| NCT01775124Macular Degeneration · China | 4 | Completed | Nov 23, 2015 | 332 |
| NCT01594281Proliferative Diabetic Retinopathy (PDR) · Germany | 2 | Completed | Nov 30, 2016 | 107 |
| NCT01599650Retinal Vein Occlusion · Australia, Canada, Czech Republic and more | 3 | Completed | May 2015 | 455 |
| NCT01580020Retinal Vein Occlusion · Germany | 4 | Completed | Oct 2014 | 175 |
| NCT01535261Macular Edema · Australia, Austria, Canada and more | 3 | Completed | Mar 2015 | 357 |
| NCT01396083Vision Disorders · Germany, Hungary, Poland and more | 3 | Completed | Jan 2014 | 243 |
| NCT01396057Vision Disorders · Czech Republic, Germany, Hungary and more | 3 | Completed | Jun 2013 | 244 |
| NCT01377597Retinal Vein Occlusion · Japan | 3 | Completed | Apr 2012 | 47 |
| NCT01315275Vision Disorders · France | 4 | Completed | Aug 2012 | 394 |
| NCT01297569Macular Edema · Norway | 4 | Completed | Nov 2012 | 7 |
| NCT01257815Diabetic Retinopathy · United Kingdom | 4 | Completed | Apr 2013 | 111 |
| NCT01217944Myopia, Degenerative · Austria, Canada, France and more | 3 | Completed | Aug 2012 | 277 |
| NCT01171976Diabetic Macular Edema · Belgium, Czech Republic, France and more | 3 | Completed | Apr 2013 | 373 |
| NCT01148511Macular Degeneration · Turkey | 4 | Completed | Apr 2012 | 99 |
| NCT01135914Vision Disorders · Canada | 3 | Completed | Mar 2013 | 241 |
| NCT01131585Visual Impairment Due to Diabetic Macular Edema · Germany | 3 | Terminated | Jul 2011 | 128 |
| NCT01037348Choroidal Neovascularization · United Kingdom | 2 | Completed | May 2012 | 65 |
| NCT00989989Edema · China, Hong Kong, Japan and more | 3 | Completed | Aug 2011 | 396 |
| NCT00967213Neovascular Age-related Macular Degeneration · Korea, Republic of | 3 | Completed | Feb 2008 | 10 |
| NCT00942864Macular Edema · Korea, Republic of | 3 | Completed | Dec 2009 | 40 |
| NCT00901186Vision Disorders · Spain | 2 | Completed | Aug 2012 | 83 |
| NCT00826371Macular Degeneration · China | 3 | Completed | Jul 2010 | 114 |
| NCT00687804Edema · Australia, Belgium, Canada and more | 3 | Completed | Jan 2010 | 345 |
| NCT00674323Polypoidal Choroidal Vasculopathy · Hong Kong, Korea, Republic of, Singapore and more | 4 | Completed | May 2009 | 61 |
| NCT00504959Macular Degeneration · Australia, Belgium, Germany and more | 4 | Completed | Jan 2010 | 234 |
| NCT00470678Choroidal Neovascularization · Korea, Republic of, Taiwan | 3 | Completed | Nov 2008 | 95 |
| NCT00331864Macular Degeneration · Switzerland | 3 | Completed | Apr 2008 | 531 |
| NCT00288561Macular Degeneration · Switzerland | 2 | Completed | ||
| NCT00284089Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) · Japan | 2 | Completed | Mar 2007 | 88 |
| NCT00284050Diabetic Macular Edema · Switzerland | 2 | Completed | Jun 2008 | 151 |
| NCT00275821Macular Degeneration · Switzerland | 3 | Completed | Jan 2008 | 353 |
How it is read
Names in the registry
- “Ranibizumab”, 40 entries
- “ranibizumab”, 18 entries
- “Ranibizumab 0.5 mg”, 11 entries
- “rhuFab V2 (ranibizumab)”, 6 entries
- “Ranibizumab 0.5mg”, 4 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 41 studies
- Macular Edema, 22 studies
- Choroidal Neovascularization, 15 studies
- Retinal Vein Occlusion, 7 studies
- Vision Disorders, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.